ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
06/10/2026
Back to search
Official data from USPTO
TANGRAM THERAPEUTICS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: US
Quick snapshot
TANGRAM THERAPEUTICS
ST13
US500000099163593Class
5, 42
Filing
99163593
Registration
8148819
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
17
Latest update
06/11/2026
Classification
Registered
Trademark type
Word
Nice classes
5, 42
Filing date
04/30/2025
Registration date
02/24/2026
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
02/24/2026
Last transaction
06/11/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Foreign priority
Drawing code
4
Owner type
84
Owner location
LONDON, GB
Examiner
SNYDER, NELSON B
Law office
L70
Current location
FILE REPOSITORY (FRANCONIA)
Holders and representatives
Holders
TANGRAM THERAPEUTICS PLC
E-THERAPEUTICS PLC
Representatives
Anna King Banner & Witcoff, Ltd.
Technical classification
Nice Classes
Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical and medical preparations for use in targeting genes and silencing or inhibiting gene expression; RNAi-based medicines and pharmaceuticals for use in targeting genes and blockingsilencinginhibiting gene expressionfor use in targeting mRNA and triggering its degradation; short interfering RNA (siRNA) medicines and pharmaceuticals for use in targeting genes and blockingsilencinginhibiting gene expressionfor use in targeting mRNA and triggering its degradation; nucleic acid-based drugs (NABDs) for blockingsilencing or inhibiting gene expression; pharmaceutical and medical preparations for use in targeting messenger RNA (mRNA) and triggering its degradation.
Class 42
Scientific research and development; pharmaceutical research and development services; drug discovery services; human genetic research; scientific and technical data analysis in the field of pharmaceuticalsmedicines and drug discovery; designdevelopmentcreation and maintenance of computer software platforms and computer software for use in the field of pharmaceuticalsmedicines and drug discovery; Platform as a Service (PaaS) featuring computer software platforms for modelling genetic sequences and gene-disease associationsfor identifying and ranking potential gene targetsfor generating pharmaceutical and medical preparationsfor use in the field of pharmaceuticalsmedicines and drug discovery; design and development of computer-simulated models; Software as a Service (SaaS) services featuring computer software for modelling genetic sequences and gene-disease associationsfor identifying and ranking potential gene targetsfor generating pharmaceutical and medical preparationsfor use in the field of pharmaceuticalsmedicines and drug discovery; software as a service (SaaS) services featuring computer software platforms using artificial intelligence and machine learning for use in the field of pharmaceuticalsmedicines and drug discoveryfor modelling genetic sequences and gene-disease associationsfor identifying and ranking potential gene targetsfor generating RNAi-based medicines and pharmaceuticalsnucleic acid-based drugs (NABDs) for blockingsilencing or inhibiting gene expressionpharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation; provision of informationadvice and consultancy services relating to all of the aforesaid.
Publications
History of USPTO decisions and trademark events.
17 publications found
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
02/24/2026
R.PR
REGISTERED-PRINCIPAL REGISTER
02/24/2026
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
01/06/2026
PUBO
PUBLISHED FOR OPPOSITION
01/06/2026
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
12/31/2025
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
12/10/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
12/08/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
12/08/2025
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
12/08/2025
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
09/20/2025
GNRT
NON-FINAL ACTION E-MAILED
09/20/2025
CNRT
NON-FINAL ACTION WRITTEN
09/20/2025
DOCK
ASSIGNED TO EXAMINER
09/19/2025
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
09/09/2025
MAFR
APPLICATION FILING RECEIPT MAILED
04/30/2025
NWAP
NEW APPLICATION ENTERED
04/30/2025
Continuous trademark protection
Get notified about every new filing that threatens TANGRAM THERAPEUTICS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.